Compare ROC & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROC | CGTX |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | 82 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.6M | 102.9M |
| IPO Year | N/A | 2021 |
| Metric | ROC | CGTX |
|---|---|---|
| Price | $5.12 | $1.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $9.00 | $3.33 |
| AVG Volume (30 Days) | 66.3K | ★ 2.4M |
| Earning Date | 03-31-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $0.55 |
| 52 Week High | $7.80 | $3.83 |
| Indicator | ROC | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 44.51 |
| Support Level | $4.42 | $1.05 |
| Resistance Level | $5.32 | $1.23 |
| Average True Range (ATR) | 0.60 | 0.17 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 62.61 | 19.88 |
Rank One Computing Corp is an American artificial intelligence company. It develops AI systems that analyze visual data to identify and interpret objects and activities. The company's focus is on biometric identity, digital forensics, and real-time video analytics. It uses the term 'Vision AI,' which is an operational AI built for accuracy, speed, and auditability. The company generates revenue from the sale of access to its software platforms, maintenance services, and professional services.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).